Endovia Health Sciences (EDVA) Registration filing summary

Company overview and business model

• Strategic pivot during FY2026 from beverage brands to regulated cannabinoid and health and wellness markets; focus on CannEpil development and commercialization plus potential strategic acquisitions.

• July 2026 license grants exclusive worldwide CannEpil rights for human neurological conditions; veterinary use was added, with initial focus on canine oncology and pain management.

• Lupvindol leads U.S. veterinary development and FDA regulatory work; the licensed product remains investigational, and no CannEpil revenue had been generated as of the prospectus date.

Financial performance and metrics

• FY2025 revenue $73,066 vs. $801,273 in FY2024; net loss $25.23M vs. $23.76M, including $14.2M of operating expenses in FY2025.

• H1 2026 revenue below $0.01M vs. ~$0.05M in H1 2025; Q2 revenue was zero in both periods. H1 2026 net loss was $4.19M vs. $12.14M.

• Cash and equivalents were $242,702 at June 30, 2026 and $330,200 at August 6, 2026; H1 operating cash use was $2.0M.

• FY2025 operating cash use was $4.8M; H1 2026 financing cash provided $2.2M, including $2.9M gross ELOC proceeds offset by $0.74M of debt repayments.

Use of proceeds and capital allocation

• Potential ELOC proceeds are intended for working capital, general corporate purposes, CannEpil development, a strategic transaction, NYSE compliance, litigation resolution and outstanding payables.

• While the September 2025 secured notes remain outstanding, 30% of ELOC proceeds received after $3M of aggregate purchases must go to repayment; noteholders waived repayment to the prospectus date.

• At least $2M is estimated as necessary for the next 12 months of CannEpil development, commercialization, working capital and general corporate needs.